November 3, 2011

Net sales up 10.1% and Business net income1 up 4.1% at CER2

- Performance driven by growth platforms, Genzyme acquisition and cost savings -

 

Net sales up 10.1% and Business net income1 up 4.1% at CER2
- Performance driven by growth platforms, Genzyme acquisition and cost savings -

Commenting on the Group’s performance in Q3 2011, Sanofi Chief Executive Officer, Christopher A. Viehbacher said, “The return to growth in sales and earnings in the third quarter reflects an important milestone as the company progressively puts the patent cliff behind it. The integration of Genzyme is progressing well. Our growth platforms3 again achieved double digit growth and more than compensated for generic erosion. We continue to make strong progress in R&D with the submission of five new products and also in the tight control of our costs.”